Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies
Hong Phuong Nguyen, Quang De Tran, Cường Quốc Nguyễn, Tran Phuong Hoa, Trần Duy Bình, Huynh Nhu Thao, Bùi Thị Bửu Huê, Nguyễn Trọng Tuân, Quang Lê Đăng, Thanh Q. C. Nguyen, Nguyen Van Ky, Minh Quan Pham, Su‐Geun Yang
Abstract
= 0.318 ± 0.049 μM). Furthermore, we also confirmed the inhibitory activity of 7f in a cellular model. Additionally, we found that the inhibitory activity of 7f against histone deacetylase 6 catalytic activity (HDAC6) is more potent than that of belinostat. Finally, we observed the strong synergistic interaction between the derivative 7f and the proteasome bortezomib inhibitor (CI = 0.26), while belinostat and bortezomib showed synergism with a CI value of 0.36. Taken together, the above results suggest that 7f is a promising HDAC inhibitor deserving further investigation.